Your browser doesn't support javascript.
loading
Evaluation of a Peer-to-Peer Data Transparency Intervention for Mohs Micrographic Surgery Overuse.
Albertini, John G; Wang, Peiqi; Fahim, Christine; Hutfless, Susan; Stasko, Thomas; Vidimos, Allison T; Leshin, Barry; Billingsley, Elizabeth M; Coldiron, Brett M; Bennett, Richard G; Marks, Victor J; Park, Angela; Overton, Heidi N; Bruhn, William E; Xu, Tim; Krishnan, Aravind; Makary, Martin A.
Afiliação
  • Albertini JG; The Skin Surgery Center, Winston Salem, North Carolina.
  • Wang P; Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina.
  • Fahim C; Department of Surgery, Johns Hopkins University, Baltimore, Maryland.
  • Hutfless S; Department of Surgery, Johns Hopkins University, Baltimore, Maryland.
  • Stasko T; Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland.
  • Vidimos AT; Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Leshin B; Department of Dermatology, University of Oklahoma, Oklahoma City.
  • Billingsley EM; Cleveland Clinic, Cleveland, Ohio.
  • Coldiron BM; The Skin Surgery Center, Winston Salem, North Carolina.
  • Bennett RG; Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina.
  • Marks VJ; Penn State Health, Hershey, Pennsylvania.
  • Park A; University of Cincinnati Hospital, Cincinnati, Ohio.
  • Overton HN; Bennett Surgery Center, Santa Monica, California.
  • Bruhn WE; Geisinger Medical Center, Danville, Pennsylvania.
  • Xu T; Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Krishnan A; Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Makary MA; Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
JAMA Dermatol ; 155(8): 906-913, 2019 Aug 01.
Article em En | MEDLINE | ID: mdl-31055597
ABSTRACT
IMPORTANCE Mohs micrographic surgery (MMS) is a skin cancer treatment that uses staged excisions based on margin status. Wide surgeon-level variation exists in the mean number of staged resections used to treat a tumor, resulting in a cost disparity and question of appropriateness.

OBJECTIVE:

To evaluate the effectiveness of a behavioral intervention aimed at reducing extreme overuse in MMS, as defined by the specialty society, by confidentially sharing stages-per-case performance data with individual surgeons benchmarked to their peers nationally. DESIGN, SETTING, AND

PARTICIPANTS:

This nonrandomized controlled intervention study included 2329 US surgeons who performed MMS procedures from January 1, 2016, to March 31, 2018. Physicians were identified using a 100% capture of Medicare Part B claims. The intervention group included physicians affiliated with the American College of Mohs Surgery, and the control group included physicians not affiliated with the American College of Mohs Surgery.

INTERVENTIONS:

Individualized performance reports were delivered to all outlier surgeons, defined by the specialty society as those with mean stages per case 2 SDs above the mean, and inlier surgeons in the intervention group. MAIN OUTCOMES AND

MEASURES:

The primary outcome was surgeon-level change in mean stages per case between the prenotification (January 2016 to January 2017) and postnotification (March 2017 to March 2018) periods. A multivariable linear regression model was used to evaluate the association of notification with this surgeon-level outcome. The surgeon-level metric of mean stages per case was not risk adjusted. The mean Medicare cost savings associated with changes in practice patterns were calculated.

RESULTS:

Of the 2329 included surgeons, 1643 (70.5%) were male and 2120 (91.0%) practiced in metropolitan areas. In the intervention group (n = 1045), 53 surgeons (5.1%) were outliers; in the control group (n = 1284), 87 surgeons (6.8%) were outliers. Among the outliers in the intervention group, 44 (83%) demonstrated a reduction in mean stages per case compared with 60 outliers in the control group (69%; difference, 14%; 95% CI of difference, -1 to 27; P = .07). There was a mean stages-per-case reduction of 12.6% among outliers in the intervention group compared with 9.0% among outliers in the control group, and outliers in the intervention group had an adjusted postintervention differential decrease of 0.14 stages per case (95% CI, -0.19 to -0.09; P = .002). The total administrative cost of the intervention program was $150 000, and the estimated reduction in Medicare spending was $11.1 million. CONCLUSIONS AND RELEVANCE Sharing personalized practice pattern data with physicians benchmarked to their peers can reduce overuse of MMS among outlier physicians.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JAMA Dermatol Ano de publicação: 2019 Tipo de documento: Article País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JAMA Dermatol Ano de publicação: 2019 Tipo de documento: Article País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA